Eiko Lifesciences promoter group stake rises to 18.18% after warrant conversion

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Lenus Finvest Private Limited acquired 1,50,000 equity shares of Eiko Lifesciences via warrant conversion
  • Promoter group holding in Eiko Lifesciences rises to 18.18% of total issued capital
  • Transaction occurred on October 16, 2026, through preferential allotment conversion
  • Total equity share capital of Eiko Lifesciences increased to 14,80,08,540 shares
powered bylight_fuzz_icon
53933372

*this image is generated using AI for illustrative purposes only.

Eiko Lifesciences Limited saw its promoter group holding increase to 18.18% following a share acquisition by Lenus Finvest Private Limited. The entity acquired 1,50,000 equity shares through warrant conversion on October 16, 2026.

Lenus Finvest Private Limited, part of the promoter group, converted 1,50,000 warrants issued on a preferential basis into equity shares. This transaction added 1.02% to its stake in the company's issued and subscribed capital.

Stakeholding details

The disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, highlights the shift in ownership structure. Prior to this transaction, Lenus Finvest held 25,40,472 shares, representing 17.34% of the total voting capital. The conversion of warrants has now consolidated these holdings into direct equity ownership.

Metric Pre-acquisition Post-acquisition
Shares held 25,40,472 26,90,472
% of total share capital 17.34% 18.18%
Warrants held 1,50,000 0

Capital structure impact

Following the allotment, Eiko Lifesciences' total equity share capital increased from 14,65,08,540 shares to 14,80,08,540 shares. Each equity share has a face value of ₹10. The total diluted share capital stands at 17,29,58,540 shares after the transaction.

What the numbers show

The transaction illustrates a consolidation of existing financial instruments into direct equity. Before the conversion, Lenus Finvest held 1,50,000 warrants which were counted separately from its 25,40,472 equity shares. By converting these warrants, the promoter group entity eliminated the dilution risk associated with these instruments while maintaining its aggregate economic interest at 18.18% of the non-diluted base. The shift reduces the number of outstanding convertible securities, potentially simplifying the company's future capital structure planning.

Historical Stock Returns for EIKO Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.63%+6.75%+12.29%-5.47%-3.77%0.0%

How will the elimination of these convertible warrants impact Eiko Lifesciences' future capital raising strategies and potential dilution risks?

What are the strategic motivations behind Lenus Finvest Private Limited's decision to convert warrants into direct equity at this specific time?

Does the promoter group's increased stake to 18.18% signal a broader intent to consolidate control or prepare for a potential takeover bid?

Eiko Lifesciences AGM resolutions pass with majority; voting details out

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • All four AGM resolutions passed with requisite majority on September 22, 2026
  • Promoter votes excluded from director re-appointment and related party transaction approvals
  • Suraj Mahadev Gaikwad appointed as Independent Director via special resolution
  • FY26 standalone and consolidated financial statements adopted by shareholders
powered bylight_fuzz_icon
51631694

*this image is generated using AI for illustrative purposes only.

Eiko Lifesciences has disclosed the voting results for its 49th Annual General Meeting held on September 22, 2026. All four resolutions proposed by the Board were passed with the requisite majority, including the adoption of FY26 financial statements and the appointment of Suraj Mahadev Gaikwad as an Independent Director.

The meeting was conducted via video conferencing in compliance with the Companies Act, 2013 and SEBI regulations. The scrutinizer's report, submitted by Shravan A. Gupta & Associates, confirmed that remote e-voting and e-voting during the AGM yielded valid results for all agenda items. Notably, promoter and promoter group votes were excluded from specific resolutions where they were deemed interested parties.

Voting results summary

The following table summarizes the voting outcome for each resolution passed during the meeting:

Resolution Type Votes in Favour Votes Against Result
Adoption of FY26 Financial Statements Ordinary 99,31,561 5 Passed
Re-appointment of Bhavesh Tanna Ordinary 42,06,773 5 Passed
Appointment of Suraj Gaikwad (ID) Special 99,31,561 5 Passed
Approval of Related Party Transactions Ordinary 42,06,773 5 Passed

Note: For Resolutions 2 and 4, promoter votes totalling 57,24,788 were treated as invalid as they are interested parties.

Board composition and attendance

The meeting was attended by 25 members through video conferencing or other audio-visual means. The requisite quorum was present at the beginning and throughout the session. Key managerial personnel and directors participated in the proceedings.

Name Designation
Laxmikant Kabra Chairman and Non-Executive Director
Bhavesh Tanna Non-Executive Director
Sumukh Vartak Whole-Time Director
Rajkumar Baheti Independent Director
Kajal Kothari Independent Director
Suraj Gaikwad Additional Independent Director
Jaid Kojar Chief Financial Officer
Chintan Doshi Company Secretary & Compliance Officer

Resolutions passed

The following items of business were transacted during the meeting:

  • Adoption of Financial Statements: Ordinary resolution to receive, consider, and adopt the Audited Standalone and Consolidated Financial Statements for FY26, along with the Reports of the Board of Directors and Auditors.
  • Re-appointment of Director: Ordinary resolution to re-appoint Bhavesh Dhirajlal Tanna (DIN: 03353445) as a Director liable to retire by rotation.
  • Appointment of Independent Director: Special resolution to appoint Suraj Mahadev Gaikwad (DIN: 11159369) as an Independent Director.
  • Related Party Transactions: Ordinary resolution to approve material related party transactions entered into or proposed to be entered into with related parties.

Proceedings summary

Chairman Laxmikant Kabra addressed the shareholders, sharing the company's vision and highlighting areas where the company may see exciting opportunities. The floor was opened for questions and answers, allowing shareholders to share their views. The Chairperson proposed a vote of thanks to the members, directors, auditors, and management before concluding the meeting at 4:54 pm IST.

The statutory auditor, M/s P S V Jain & Associates, Chartered Accountants, and the secretarial auditor, M/s Shravan A. Gupta & Associates, were present via video conferencing. The scrutiniser's representative also attended the meeting.

Historical Stock Returns for EIKO Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.63%+6.75%+12.29%-5.47%-3.77%0.0%

What specific strategic initiatives did Chairman Laxmikant Kabra highlight as key growth opportunities for Eiko Lifesciences in the coming fiscal year?

How will the appointment of Suraj Mahadev Gaikwad as an Independent Director influence the company's governance framework and board diversity metrics?

What are the projected financial impacts of the approved material related party transactions on Eiko Lifesciences' FY27 revenue and margin structure?

More News on EIKO Lifesciences

1 Year Returns:-3.77%